


FIG. 1B




FIG. 1A



Adj Ratio Ap+Necr to Viable
60
50
40
30
20
10
0
H157
No Drug
MS275 0.5uM
MS275 2uM
MS275 4uM
Gefitinib 10 uM
Gefitinib 12 uM
Gefitinib 14 uM
MS275 0.5uM/ Gefitinib 10uM
MS275 0.5uM/ Gefitinib 12uM
MS275 0.5uM/ Gefitinib 14uM
MS275 2uM/ Gefitinib 10uM
MS275 2uM/ Gefitinib 12uM
MS275 2uM/ Gefitinib 14uM
MS275 4uM/ Gefitinib 10uM
MS275 4uM/ Gefitinib 12uM
MS275 4uM/ Gefitinib 14uM

FIG. 2